Peter E M Taschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2213252/publications.pdf

Version: 2024-02-01

64 papers 8,250 citations

36 h-index 66 g-index

69 all docs 69 docs citations

69 times ranked

13365 citing authors

#	Article	IF	Citations
1	Mutations in <i>SDHD</i> , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma. Science, 2000, 287, 848-851.	12.6	1,554
2	HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Human Mutation, 2016, 37, 564-569.	2.5	1,194
3	LOVD v.2.0: the next generation in gene variant databases. Human Mutation, 2011, 32, 557-563.	2.5	854
4	The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery. Human Mutation, 2015, 36, 915-921.	2.5	390
5	Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Human Mutation, 2008, 29, 6-13.	2.5	383
6	LOVD: Easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box―approach. Human Mutation, 2005, 26, 63-68.	2.5	235
7	Mutations in the gene–encoding SERCA1, the fast–twitch skeletal muscle sarcoplasmic reticulum Ca2+ ATPase, are associated with Brody disease. Nature Genetics, 1996, 14, 191-194.	21.4	223
8	Spectrum of Mutations in the Batten Disease Gene, CLN3. American Journal of Human Genetics, 1997, 61, 310-316.	6.2	181
9	Targeted Disruption of the Cln3 Gene Provides a Mouse Model for Batten Disease. Neurobiology of Disease, 1999, 6, 321-334.	4.4	180
10	The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Medical Genetics, 2005, 6, 39.	2.1	164
11	Characterization of the Gene Encoding Human Sarcolipin (SLN), a Proteolipid Associated with SERCA1: Absence of Structural Mutations in Five Patients with Brody Disease. Genomics, 1997, 45, 541-553.	2.9	159
12	Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy Volunteers. Anesthesiology, 2004, 100, 120-133.	2.5	152
13	Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHDgene. Genes Chromosomes and Cancer, 2001, 31, 274-281.	2.8	149
14	Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene, 2004, 23, 4076-4083.	5.9	146
15	Polymorphism of μ-Opioid Receptor Gene (OPRM1:c.118A>GÂ) Does Not Protect Against Opioid-induced Respiratory Depression despite Reduced Analgesic Response. Anesthesiology, 2005, 102, 522-530.	2.5	146
16	Molecular Analysis of SALL1 Mutations in Townes-Brocks Syndrome. American Journal of Human Genetics, 1999, 64, 435-445.	6.2	129
17	Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits [published erratum appears in Hum Mol Genet 1998 Apr;7(4):765]. Human Molecular Genetics, 1998, 7, 291-297.	2.9	122
18	Adult neuronal ceroid lipofuscinosis with palmitoylâ€protein thioesterase deficiency: First adultâ€onset patients of a childhood disease. Annals of Neurology, 2001, 50, 269-272.	5 . 3	113

#	Article	IF	CITATIONS
19	Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Medical Genetics, 2006, 7, 1.	2.1	112
20	In search of triallelism in Bardet–Biedl syndrome. European Journal of Human Genetics, 2012, 20, 420-427.	2.8	111
21	Replication of an incomplete alfalfa mosaic virus genome in plants transformed with viral replicase genes. Virology, 1991, 181, 445-450.	2.4	102
22	Locus Reference Genomic sequences: an improved basis for describing human DNA variants. Genome Medicine, 2010, 2, 24.	8.2	100
23	SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. Journal of Pathology, 2003, 201, 480-486.	4.5	83
24	Deep sequencing to reveal new variants in pooled DNA samples. Human Mutation, 2009, 30, 1703-1712.	2.5	71
25	Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes and Cancer, 2001, 31, 255-263.	2.8	70
26	Visual disorders in children with brain lesions:. European Journal of Paediatric Neurology, 2001, 5, 115-119.	1.6	70
27	Phenotypic dichotomy in mitochondrial complex II genetic disorders. Journal of Molecular Medicine, 2001, 79, 495-503.	3.9	67
28	Linkage of Gitelman syndrome to the thiazide-sensitive sodium-chloride cotransporter gene with identification of mutations in Dutch families. Pediatric Nephrology, 1996, 10, 403-407.	1.7	63
29	Replicase-Mediated Resistance to Alfalfa Mosaic Virus. Virology, 1995, 207, 467-474.	2.4	59
30	Describing structural changes by extending HGVS sequence variation nomenclature. Human Mutation, 2011, 32, 507-511.	2.5	57
31	Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Human Genetics, 1999, 104, 219-225.	3.8	52
32	Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma. PLoS ONE, 2009, 4, e7987.	2.5	49
33	A germline chromothripsis event stably segregating in 11 individuals through three generations. Genetics in Medicine, 2016, 18 , 494 - 500 .	2.4	48
34	Genomic Structure and Complete Nucleotide Sequence of the Batten Disease Gene, CLN3. Genomics, 1997, 40, 346-350.	2.9	47
35	Mutalyzer 2: next generation HGVS nomenclature checker. Bioinformatics, 2021, 37, 2811-2817.	4.1	44
36	Curating gene variant databases (LSDBs): Toward a universal standard. Human Mutation, 2012, 33, 291-297.	2.5	41

3

#	Article	IF	Citations
37	Caenorhabditis elegans as a model for lysosomal storage disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 433-446.	3.8	40
38	Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. European Journal of Endocrinology, 2005, 152, 87-94.	3.7	39
39	Genetic Mapping of the Batten Disease Locus (CLN3) to the Interval D16S288-D16S383 by Analysis of Haplotypes and Allelic Association. Genomics, 1994, 22, 465-468.	2.9	33
40	A Murine Model for Juvenile NCL: Gene Targeting of MouseCln3. Molecular Genetics and Metabolism, 1999, 66, 309-313.	1.1	31
41	A high-resolution integrated map spanning the SDHD gene at $11q23$: a 1.1 -Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. European Journal of Human Genetics, 2001 , 9 , 121 - 129 .	2.8	31
42	Why and how to assess the aetiological diagnosis of children with intellectual disability/mental retardation and other neurodevelopmental disorders: description of the Finnish approach. European Journal of Paediatric Neurology, 2001, 5, 7-13.	1.6	29
43	Recommendations for Analyzing and Reporting (i>TP53 (i) Gene Variants in the High-Throughput Sequencing Era. Human Mutation, 2014, 35, 766-778.	2.5	29
44	Plants Transformed with a Mutant Alfalfa Mosaic Virus Coat Protein Gene Are Resistant to the Mutant but Not to Wild-Type Virus. Virology, 1994, 203, 269-276.	2.4	27
45	Characterizing pathogenic processes in Batten disease: Use of small eukaryotic model systems. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 906-919.	3.8	26
46	An efficient algorithm for the extraction of HGVS variant descriptions from sequences. Bioinformatics, 2015, 31, 3751-3757.	4.1	25
47	Hereditary Paraganglioma Due to the SDHD M1I Mutation in a Second Chinese Family: A Founder Effect?. Laryngoscope, 2003, 113, 1055-1058.	2.0	20
48	Late onset juvenile neuronal ceroid-lipofuscinosis with granular osmiophilic deposits (GROD). American Journal of Medical Genetics Part A, 1995, 57, 165-167.	2.4	18
49	A formalized description of the standard human variant nomenclature in Extended Backus-Naur Form. BMC Bioinformatics, 2011, 12, S5.	2.6	18
50	Human Variome Project Quality Assessment Criteria for Variation Databases. Human Mutation, 2016, 37, 549-558.	2.5	18
51	VarioML framework for comprehensive variation data representation and exchange. BMC Bioinformatics, 2012, 13, 254.	2.6	17
52	Refined localization of the Batten disease gene (CLN3) by haplotype and linkage disequilibrium mapping to D16S288-D16S383 and exclusion from this region of a variant form of Batten disease with granular osmiophilic deposits. American Journal of Medical Genetics Part A, 1995, 57, 312-315.	2.4	16
53	First-trimester diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) using PPT enzyme assay and CLN1 mutation analysis., 1999, 19, 559-562.		15
54	Deletion of the Caenorhabditis elegans homologues of the CLN3 gene, involved in human juvenile neuronal ceroid lipofuscinosis, causes a mild progeric phenotype. Journal of Inherited Metabolic Disease, 2005, 28, 1065-1080.	3.6	15

#	Article	IF	CITATION
55	Carrier detection of Batten disease (Juvenile neuronal ceroid-lipofuscinosis). American Journal of Medical Genetics Part A, 1995, 57, 333-337.	2.4	13
56	Physical map of the region containing the gene for Batten disease (CLN3). American Journal of Medical Genetics Part A, 1995, 57, 316-319.	2.4	10
57	The Molecular Basis of GROD-Storing Neuronal Ceroid Lipofuscinoses in Scotland. Molecular Genetics and Metabolism, 1999, 66, 245-247.	1.1	10
58	YAC and Cosmid Contigs Spanning the Batten Disease (CLN3) Region at 16p12.1–p11.2. Genomics, 1995, 29, 478-489.	2.9	8
59	Genetic Heterogeneity of Neuronal Ceroid Lipofuscinosis in the Netherlands. Molecular Genetics and Metabolism, 1999, 66, 339-343.	1.1	8
60	Carotid Body Tumors in Humans Caused by a Mutation in the Gene for Succinate Dehydrogenase D (SDHD). Advances in Experimental Medicine and Biology, 2004, 551, 71-76.	1.6	8
61	Isolation of genes from the Batten candidate region using exon amplification. American Journal of Medical Genetics Part A, 1995, 57, 320-323.	2.4	5
62	Caenorhabditis elegans homologues of the CLN3 gene, mutated in juvenile neuronal ceroid lipofuscinosis. European Journal of Paediatric Neurology, 2001, 5, 115-120.	1.6	4
63	Application of chromosome 16 markers in the differential diagnosis of neuronal ceroid-lipofuscinosis. American Journal of Medical Genetics Part A, 1995, 57, 338-343.	2.4	3
64	Preserving sequence annotations across reference sequences. Journal of Biomedical Semantics, 2014, 5. S6.	1.6	3